These qualities would appear to make HER2 an attractive molecule for targeted immunotherapies in women with HER2-positive ovarian cancer, where naturally-occurring CD4+ and CD8+ T cell responses have been observed [8]. Here, ERBB2 is linked to ovarian carcinoma.